KEY TAKEAWAYS
Losartan eye drops, a compounded off-label formulation of the angiotensin II receptor blocker, aim to modulate corneal healing by reducing fibrosis and scarring. They target TGF-β pathways to limit myofibroblast activity and excess extracellular matrix deposition, helping preserve corneal clarity after injury, surgery (e.g., PRK/PTK), chemical burns, infections, or inflammatory conditions. The primary purpose is to minimize haze, opacity, and vision loss during the healing process under ophthalmologist supervision.
The cornea plays a vital role in our vision, acting as the eye’s clear front surface and allowing light to enter smoothly and focus properly. However, following injury, surgery, or infection, the healing process can sometimes lead to scarring, which may impair visual clarity.
In many cases, standard treatment focuses primarily on managing symptoms while the natural healing response unfolds. Because of this, healthcare providers are exploring supportive options—such as Losartan Eye Drops—that may help modulate corneal healing pathways when used under appropriate medical supervision.
What Is Corneal Scarring
Corneal scarring refers to the formation of opaque or irregular tissue on the normally clear front surface of the eye, which can affect how light passes through and reduce visual clarity. It happens when the cornea’s delicate structure is disrupted by injury, infection, inflammation, or other insults that trigger a wound-healing response.
Because the cornea is key in focusing light onto the retina, changes to its transparency can lead to blurred or hazy vision and difficulty with tasks such as reading or driving.
Common Signs and Symptoms
- Blurry or hazy vision due to disruption of the corneal surface
- Sensitivity to bright light or glare
- Redness, tearing, or discomfort indicating irritation or ongoing surface changes
- A sensation of something in the eye, especially when the surface is irregular
The severity and impact of scarring depend on its location and depth. Thus, scars that lie directly in the line of sight tend to have a greater effect on vision than those on the cornea’s periphery.
Why Early Attention Matters
The cornea needs to heal smoothly to stay clear. When scarring develops or continues to change, even small surface irregularities may affect how light enters the eye, making daily tasks feel more difficult.
Paying attention to these changes early helps eye care specialists better understand how the cornea is healing over time. In some situations, this awareness may guide conversations about additional ways to support the healing process under professional care.
Exploring Losartan for Corneal Health
Losartan is a well-established medication for managing high blood pressure, functioning by blocking angiotensin II receptors that contribute to blood vessel constriction
Given the complex cellular signaling involved in corneal healing, researchers have begun exploring whether losartan’s activity on these pathways could help support the repair and regeneration of corneal tissue after injury or surgery.
“Losartan, traditionally an antihypertensive, has gained attention in ophthalmology for its anti-fibrotic and anti-inflammatory properties. Studies have supported its efficacy in reducing corneal fibrosis post-descemetorhexis, alkali burn, and PRK injuries in animal models, and human case reports.”
Mechanism of Action
Losartan’s potential role in corneal healing relates to how it may influence cellular signaling rather than eye pressure or fluid flow. In particular, researchers study its interaction with transforming growth factor-beta (TGF-β), a pathway involved when certain healing cells contribute to scar formation and affect corneal clarity.
Possible Side Effects
- Temporary stinging or burning upon application
- Mild redness of the eye
- Short-term irritation or discomfort
An ophthalmologist may prescribe Losartan as an option after evaluating standard care and adjunctive support considerations for corneal scarring or healing-related changes affecting the eye.
When Might a Practitioner Prescribe Losartan Eye Drops for Corneal Healing?
While losartan is widely known for its role in cardiovascular health, its emerging use in ophthalmology—particularly in modulating corneal fibrosis—has prompted increasing interest among eye care providers and specialists managing complex ocular surface conditions. Although this is an off-label application, compounded topical losartan eye drops may be considered in specific clinical scenarios where standard therapies have limited impact on scar modulation or stromal healing.
Here are a few common scenarios where a practitioner might consider prescribing compounded losartan eye drops:
1. Post-Surgical Corneal Haze or Scarring (e.g., PRK or PTK)
Patients who develop haze following surface refractive procedures such as photorefractive keratectomy (PRK) or phototherapeutic keratectomy (PTK) may be candidates. In these cases, losartan eye drops may be explored to help limit myofibroblast activity and reduce extracellular matrix remodeling, both of which contribute to haze formation and visual distortion.
2. Delayed or Irregular Healing After Corneal Injury
For patients recovering from corneal trauma, abrasions, or chemical burns, where healing is incomplete or complicated by early signs of fibrosis, losartan may be considered as part of a multi-modal healing strategy. This is particularly relevant when the epithelium has healed but stromal haze or irregular remodeling is a concern.
3. Recurrent or Persistent Corneal Scarring in Inflammatory Conditions
In chronic ocular surface diseases—such as severe dry eye, limbal stem cell deficiency, or neurotrophic keratopathy—ongoing inflammation and poor healing can result in subepithelial or stromal fibrosis. Providers may consider losartan drops in such complex cases when traditional anti-inflammatories or lubricants are insufficient in halting fibrotic progression.
4. Adjunct in Keratoconus Management Post-CXL
While early evidence is limited, some practitioners have explored the use of losartan eye drops following corneal crosslinking (CXL) in keratoconus patients, based on its potential to modulate abnormal matrix remodeling. The goal is not to halt the ectatic process but to influence how the cornea heals and stabilizes post-treatment.
5. Complication Management: Corneal Scarring After Infectious Keratitis
After resolution of bacterial, fungal, or herpetic keratitis, residual scarring can impact vision despite infection control. In select patients, losartan eye drops may be considered to influence the healing pathway during the post-infectious phase, once the epithelium is stable and infection is no longer active.
6. Patients Prone to Excessive or Dense Corneal Scarring
Some individuals are known to form dense fibrotic tissue in response to eye procedures or trauma, increasing the likelihood of post-surgical haze, visual distortion, or compromised outcomes. These patients may include those with:
- Previous history of hypertrophic ocular scarring
- Underlying inflammatory conditions
- Darker iris pigmentation (associated in some studies with increased haze risk)
- History of aggressive wound healing in other surgeries
In such patients, losartan may be considered proactively or early post-op as part of a strategy to modulate fibrotic activity and optimize visual recovery—particularly after procedures like PRK, PTK, or corneal grafting.
Prescribing Considerations
- Prescription Required: As a non-commercial formulation, losartan ophthalmic drops must be prescribed and compounded by a sterile, PCAB-accredited pharmacy.
- Treatment Duration: Often initiated for 4–12 weeks, depending on response, under close clinical monitoring.
Multidisciplinary Collaboration: Particularly helpful when coordinated between ophthalmology, optometry, or other specialists managing ocular surface disease.
What Research Says About Losartan for Corneal Health
Losartan and Corneal Scarring
A pivotal preclinical study published in PLOS ONE demonstrated that topical 0.8% losartan significantly reduced corneal scarring and haze following epithelial injury and irregular PTK in a rabbit model. The treatment group exhibited fewer myofibroblasts (α-SMA–positive cells) and reduced deposition of extracellular matrix proteins such as fibronectin and type III collagen—key contributors to visually significant corneal fibrosis.Â
These findings support the hypothesis that losartan may be a valuable adjunct in managing corneal healing, particularly in procedures or conditions where TGF-β–driven myofibroblast activity leads to haze. By targeting the angiotensin II type 1 receptor (AT1R), losartan helps downregulate this fibrotic response at both the cellular and matrix level. Importantly, no toxicity or delayed healing was observed in this study, reinforcing its potential safety for ophthalmic use.
Source: PLoS One
Topical Losartan in the Management of Corneal Scarring Fibrosis
A journal article review examined how losartan has been explored in research involving corneal injury, with attention to how it may influence healing processes associated with scarring.
The authors summarized findings from published research and case reports involving topical losartan use after different types of corneal injury, including surgical procedures, chemical exposure, and surface reshaping.
- Research models showed patterns suggesting losartan may influence cellular activity linked to fibrotic scarring during corneal healing.
- Case-based reports described observations where off-label losartan use was associated with changes in scarring following surgical or infection-related corneal complications.
Losartan Considerations for Corneal HealingÂ
Researchers have reviewed available studies to better understand how losartan has been examined in relation to corneal scarring and the healing process.
In cases involving corneal injury—including surgical procedures, chemical exposure, and surface trauma—both preclinical and clinical observations have been reported. Animal studies have described patterns suggesting that topical losartan may influence fibrotic activity during corneal healing. Additionally, limited human case reports have noted changes in scarring behavior following corneal injury or surgical complications when off‑label topical losartan was used under medical supervision.
Source: Journal of Ocular Pharmacology and Therapeutics
Losartan and Corneal Scar-Related Cell Activity
This research examined how off-label losartan, alone and alongside a commonly used corticosteroid, was evaluated for its potential relationship to corneal scarring processes in a controlled setting.
Investigators used preclinical models of corneal injury to observe how topical losartan, by itself or combined with prednisolone acetate, related to cellular activity associated with stromal scarring during healing.
- Adding topical losartan was associated with patterns suggesting changes in the activity of stromal cells involved in scarring, compared with control conditions without losartan.
- When losartan and prednisolone acetate were evaluated together, observations suggested combined effects on cell behavior linked to scar-forming pathways.
Compounded Losartan Eye Drops
In ophthalmic care, compounding allows medications to be prepared in ways that align more closely with an individual patient’s needs. When losartan is considered as an adjunct, the process involves collaboration between an ophthalmologist and a compounding pharmacist.
Losartan eye drops are not commercially available and must be compounded by a licensed compounding pharmacy. Let’s go into how the compounding process generally works.
How Losartan Eye Drops Are Compounded
1. Active Ingredient Sourcing
The process begins with USP-grade losartan potassium, the same active pharmaceutical ingredient (API) used in oral formulations. This ingredient must be sourced from a trusted, FDA-registered supplier to ensure purity and consistency.
2. Sterile Compounding Environment
Because eye drops must be sterile, losartan ophthalmic solutions are prepared in a cleanroom environment that meets USP <797> or USP <800> standards for sterile compounding. This ensures the medication is free from microbial contamination, which is critical for safety in ocular use.
3. Formulation and Concentration
Pharmacists compound losartan into a sterile aqueous solution, typically at concentrations like 0.8%, 1.0%, or another strength depending on the prescriber’s direction. The concentration and pH are carefully adjusted to make the solution tolerable to the eye and therapeutically effective.
4. Preservative-Free or Preserved Formulations
Depending on the patient’s needs, the drops can be compounded preservative-free or with appropriate ophthalmic preservatives for multi-use bottles. Preservative-free options are often preferred for patients with sensitive eyes or long-term use.
5. Sterile Filtration & Packaging
After compounding, the solution is passed through a 0.22-micron filter to achieve sterility and then transferred into sterile, ophthalmic-grade dropper bottles or unit-dose vials.
6. Labeling & Stability
The compounded product is labeled with:
- Strength/concentration
- Expiration date (based on available stability data)
- Storage instructions (e.g., refrigeration if required)
- Usage instructions
Michigan’s PCAB-Accredited Sterile Compounding Pharmacy for Corneal Health & Ophthalmology
Healing Dose Compounding Pharmacy supports eye care teams and patients by addressing complex medication needs through customized ophthalmic compounding.Â
We work collaboratively with eye care professionals to help support individualized care plans when commercially available options may not align with specific clinical goals.
When managing ophthalmic medications, safety and quality are essential.
- PCAB-Accredited: Our pharmacy holds accreditation for both sterile and non-sterile compounding.
- USP <797> Standards: We adhere to rigorous standards, ensuring every drop is prepared in a state-of-the-art sterile environment.
- Our Reach: We are licensed to ship prescriptions to Michigan as well as FL, IN, MN, OH, and WI. Over-the-counter (OTC) products are shipped nationwide.
For patients, our pharmacists are available to answer questions about compounded ophthalmic medications and how they may be designed to support your individual needs under the guidance of an eye care specialist.
For ophthalmologists, we offer a streamlined prescribing experience with clear, detailed order forms developed specifically for ophthalmic compounding. Our team is available to collaborate on formulations intended to support corneal health and other specialized ocular considerations.
References:
- Abdelghaffar, M., GĂĽell, J. L., & Moura-Coelho, N. (2025). Topical losartan ophthalmic drops–a review of corneal wound healing and topical losartan for managing corneal haze and potential future indications. Graefe’s Archive for Clinical and Experimental Ophthalmology, 263(4), 925-934. Link
- Dutra, B. A., & Wilson, S. E. (2025b). Topical losartan in the management of corneal scarring fibrosis: Update on dosage, efficacy, and potential epithelial toxicity. Journal of Ocular Pharmacology and Therapeutics, 41(5), 232–236. Link
- Mohammad, M., Qassem, A., & Darwish, T. (2025). Topical losartan treatment for corneal scarring after infectious keratitis: Case report. J Clin Images Med Case Rep, 6(7), 3683. Link
- Quigley, H. A., Pitha, I. F., Welsbie, D. S., Nguyen, C., Steinhart, M. R., Nguyen, T. D., … & Kimball, E. C. (2015). Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. PLoS One, 10(10), e0141137. Link
- Sampaio, L. P., Hilgert, G. S. L., Shiju, T. M., Santhiago, M. R., & Wilson, S. E. (2022b). Topical losartan and corticosteroid additively inhibit corneal stromal myofibroblast generation and scarring fibrosis after alkali burn injury. Translational Vision Science & Technology, 11(7), 9. Link
- Wilson, S. E. (2023c). Topical Losartan: Practical guidance for clinical trials in the prevention and treatment of corneal scarring fibrosis and other eye diseases and disorders. Journal of Ocular Pharmacology and Therapeutics, 39(3), 191–206. Link
- Valle, L. V., Alfaro, M. L., & Burchard, J. V. (2025). Treatment with losartan for visual rehabilitation post infectious keratitis: Case report. Archivos de la Sociedad Española de OftalmologĂa (English Edition), 502441. Link
- Wilson, S. E. (2024). Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan. Experimental Eye Research, 242, 109884. Link
